Johanna Kaufmann, PhD, is a scientific leader in immuno-oncology with broad expertise across preclinical and translational drug development, a strategic department head, and a passionate company builder. She is currently Chief Scientific Officer at Deck Bio, an early-stage oncology start-up in Cambridge, MA, developing innovative T cell engagers for solid tumors. Before joining Deck Bio, she served as Executive Vice President of Oncology and Immunology at Codagenix, establishing a dedicated Oncology department, translating the utility of their platform technology across disease areas, and serving as site head of one of two hubs for the company. She previously was a Scientific Director at GSK, leading an immune biology group and supporting the progression of multiple portfolio assets as part of the immuno-oncology senior leadership team. Dr. Kaufmann joined GSK through the acquisition of TESARO, where she led mechanism of action studies for multiple immuno-oncology assets. She started her industry career at Genocea Biosciences, where she headed three preclinical herpes virus vaccine programs. Dr. Kaufmann earned a MS in Molecular Medicine from Friedrich-Alexander University in Erlangen, Germany, and a PhD in Cancer Virology from the German Cancer Research Center (DKFZ) and Heidelberg University, Germany.